Subscribe

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ)

CNY15.31 +0.58 (+3.94%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address No. 800, East Road 312500
Xinchang, CN
CEO Lv Gang
Website jingxinpharm.com
IPO 2004-07-15
ISIN CNE000001K73

Explore sections of this company profile

Description

Zhejiang Jingxin Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the full spectrum of pharmaceutical activities, from research and development to manufacturing and sales within the country. Its diverse product line includes active pharmaceutical ingredients (APIs), along with a wide array of finished medications such as antihypertensives, various antibiotics (including quinolones and cephalosporins), gastrointestinal remedies, antidiabetics, antipileptics, antihistamines, H+ pump inhibitors, H2 receptor blockers, cholesterol-lowering drugs, and antidepressants, as well as biopharmaceutical products. Additionally, the company is a provider of advanced medical display solutions, offering diagnostic, surgical, clinical, large-screen, integrated, and ultrasonic medical displays. Originally founded in 1974 as Zhejiang Jingxin Pharmaceutical Factory, the company officially rebranded to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000 and maintains its headquarters in Xinchang, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY15.31 +0.58 (+3.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
12M
Beta
-0.12
Float Shares
547.24M
Free Float %
63.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.66% -5.08% -10.04% -17.75% -32.19% -29.19% +2.28% -14.94% +49.33% +47.37% +572.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
15.31
DCF (Unlevered) 47.81 +212.3%
DCF (Levered) 30.54 +99.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 0 -1
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.32
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -2.1% Q1'26: -3.5% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +10.8% Q1'26: +0.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +14.0% ★ Q1'26: +10.1% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +21.3% ★ Q1'26: +20.9% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +16.7% ★ Q1'26: +12.9% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -4.0% ★ Q1'26: +1.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.27× ★ Q1'26: 0.20× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.07) × ERP
WACC = 97% × Ke + 3% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 48.28 Current price: 15.31
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
1.42B
est: 1.59B (-11.1%)
1.88B
est: 1.82B (+3.0%)
2.22B
est: 2.21B (+0.5%)
2.94B
est: 2.94B (0.0%)
3.65B
est: 3.84B (-5.0%)
3.26B
est: 3.85B (-15.5%)
3.47B
est: 4.60B (-24.6%)
3.78B
est: 3.65B (+3.5%)
4.00B
est: 4.00B (0.0%)
4.16B
est: 4.46B (-6.8%)
4.07B
est: 4.52B (-10.0%)
4.57B
4.57B – 4.57B
+1.1% YoY
5.17B
5.17B – 5.17B
+13.0% YoY
5.65B
5.65B – 5.65B
+9.4% YoY
EBITDA
219.26M
est: 331.26M (-33.8%)
303.07M
est: 378.62M (-20.0%)
336.93M
est: 459.13M (-26.6%)
465.34M
est: 612.45M (-24.0%)
592.21M
est: 798.53M (-25.8%)
642.51M
est: 801.93M (-19.9%)
713.89M
est: 955.92M (-25.3%)
766.56M
est: 759.94M (+0.9%)
784.87M
est: 832.13M (-5.7%)
989.48M
est: 1.65B (-39.9%)
1.16B
est: 1.67B (-30.7%)
1.69B
1.69B – 1.69B
+1.1% YoY
1.91B
1.91B – 1.91B
+13.0% YoY
2.08B
2.08B – 2.08B
+9.4% YoY
EBIT
160.39M
est: 256.40M (-37.4%)
223.11M
est: 293.06M (-23.9%)
250.22M
est: 355.37M (-29.6%)
374.43M
est: 474.04M (-21.0%)
486.00M
est: 618.07M (-21.4%)
519.31M
est: 620.71M (-16.3%)
577.80M
est: 739.90M (-21.9%)
613.80M
est: 588.20M (+4.4%)
579.08M
est: 644.08M (-10.1%)
714.56M
est: 1.17B (-38.8%)
868.28M
est: 1.18B (-26.6%)
1.20B
1.20B – 1.20B
+1.1% YoY
1.35B
1.35B – 1.35B
+13.0% YoY
1.48B
1.48B – 1.48B
+9.4% YoY
Net Income
166.04M
est: 196.58M (-15.5%)
199.75M
est: 250.19M (-20.2%)
264.38M
est: 273.42M (-3.3%)
369.28M
est: 364.56M (+1.3%)
520.40M
est: 514.67M (+1.1%)
653.07M
est: 271.63M (+140.4%)
612.54M
est: 335.97M (+82.3%)
662.25M
est: 694.81M (-4.7%)
618.90M
est: 686.23M (-9.8%)
711.96M
est: 708.55M (+0.5%)
757.98M
est: 757.98M (0.0%)
811.53M
811.53M – 811.53M
+7.1% YoY
996.91M
996.91M – 996.91M
+22.8% YoY
1.09B
1.09B – 1.09B
+9.1% YoY
SGA
529.02M
est: 435.84M (+21.4%)
748.87M
est: 498.16M (+50.3%)
841.72M
est: 604.08M (+39.3%)
1.28B
est: 805.81M (+58.2%)
1.58B
est: 1.05B (+50.7%)
1.17B
est: 1.06B (+11.1%)
969.11M
est: 1.26B (-22.9%)
984.49M
est: 999.87M (-1.5%)
994.25M
est: 1.09B (-9.2%)
915.04M
est: 1.02B (-10.3%)
548.32M
est: 1.03B (-47.0%)
1.05B
1.05B – 1.05B
+1.1% YoY
1.18B
1.18B – 1.18B
+13.0% YoY
1.29B
1.29B – 1.29B
+9.4% YoY
EPS
0.24
est: 0.23 (+4.7%)
0.26
est: 0.29 (-10.9%)
0.33
est: 0.32 (+3.0%)
0.43
est: 0.43 (+0.2%)
0.64
est: 0.60 (+6.7%)
0.83
est: 0.32 (+160.6%)
0.75
est: 0.39 (+91.5%)
0.77
est: 0.81 (-4.9%)
0.72
est: 0.80 (-10.0%)
0.83
est: 0.86 (-3.5%)
0.92
est: 0.92 (+0.0%)
0.99
0.99 – 0.99
+7.1% YoY
1.21
1.21 – 1.21
+22.8% YoY
1.32
1.32 – 1.32
+9.1% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-28 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-27 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-26 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-25 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-22 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-21 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-20 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-19 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-18 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-15 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-14 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-13 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-12 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-11 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-08 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-07 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-06 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-30 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-29 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-28 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-27 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-24 A- 4/5 5/5 4/5 5/5 2/5 3/5 2/5
2026-04-23 A- 4/5 5/5 4/5 5/5 2/5 2/5 2/5
2026-04-22 A- 4/5 5/5 4/5 5/5 2/5 2/5 2/5
2026-04-21 A- 4/5 5/5 4/5 5/5 2/5 2/5 2/5
2026-04-20 A- 4/5 5/5 4/5 5/5 2/5 2/5 2/5
2026-04-17 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-04-16 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
609.62M
OE per share TTM
0.75
Owner's Yield
5.49%
Maintenance CapEx ratio
62.27%
Maint CapEx / Avg PPE
44.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 21 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 State Street SPDR S&P Emerging Asia Pacific ETF GMF 0.01% 55.9K 0.49%
2 State Street SPDR Portfolio Emerging Markets ETF SPEM 0.00% 693.1K 0.07%
3 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 378.4K 0.29%
4 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 340.1K 0.39%
5 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.00% 415.1K 0.06%
6 Dimensional - Emerging Markets Value ETF DFEV 0.00% 57.4K 0.46%
7 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.00% 14.1K 0.44%
8 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 140.1K 0.28%
9 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 32.9K 0.26%
10 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 14.6K 0.48%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
222.1K
Shares Outstanding
861.03M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chen Meili Vice President, Chief Financial Officer & Director — female
Jin Zhiping Vice President & Director — male
Jun Min Wang Vice President — male
Lv Gang President & Chairman of the Board — male
Sheng Liu Vice President — male
Ye Zhen Zhou Accounting Supervisor — —
Yunfei Hong Secretary of the Board & Non-Independent Director — male
Zhi Bin Zhu Vice President — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic